Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
WINDSOR, Conn., March 26, 2018 -- Scapa Healthcare, a trusted strategic outsource partner of skin-friendly, turnkey solutions, today announced the acquisition of Dallas, TX-based BioMed Laboratories. BioMed is a leading business-to-business developer and manufacturer of topical skin care solutions for advanced wound care, ostomy and consumer wellness markets.
Serving similar customer bases, BioMed is Scapa Healthcare’s first adjacent platform. The acquisition broadens Scapa’s offerings beyond adhesive-based solutions to now include complementary skin care offerings such as tubed hydrogel, wound cleansers, moisturizers and more. BioMed’s portfolio of products includes gels, creams, lotions, liquids, powders and hot fill waxes.
The addition of BioMed strengthens Scapa Healthcare’s offerings to its customers in the advanced wound care and ostomy markets, and expands market accessibility within consumer wellness segments such as OTC, first aid and health and beauty.
“At Scapa Healthcare, we remain committed to being the trusted strategic outsource partner of choice for our customers,” said Joe Davin, President Scapa Healthcare. “The acquisition of BioMed is in line with our continued growth strategy. We continue to expand our capabilities and product offerings while maintaining the level of excellence our partners expect.”
BioMed’s quality system is certified to ISO 13485 standards, and complies with FDA cGMP, Health Canada and EU regulatory requirements.
For more information on the acquisition, please visit http://www.scapa.com/en/news/AcquisitionofBioMedLaboratoriesLLC.
Learn more about BioMed Laboratories
About Scapa Healthcare
Scapa Healthcare is a global trusted strategic outsource partner of skin-friendly turnkey solutions for advanced wound care, consumer wellness and medical device markets. Scapa Healthcare partners with market leaders to design, develop, manufacture and commercialize innovative skin contact solutions to meet end-user needs. Scapa Healthcare offers turn-key development services, including design and project management; coating; converting, perforation and assembly; printing and packaging; and sterilization services. For more information, visit: www.scapahealthcare.com
Media Contact Jordan Bouclin SVM Public Relations and Marketing Communications [email protected] (401) 490-9700 Scapa Healthcare Contact Scapa Healthcare Marketing Communications Manager [email protected] (860) 902-8157
